CLINICAL TRIALS PROFILE FOR LOCOID

All Clinical Trials for LOCOID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00693693 ↗	Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis	Completed	Wake Forest University	Phase 4	2006-11-01	The purpose of this research study is to better understand adherence to Locoid when people use it to treat atopic dermatitis.
NCT00871208 ↗	Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy	Withdrawn	GlaxoSmithKline	Phase 4	2009-05-01	This study is designed to determine whether the addition of topical Altabax (R) to a treatment regimen of topical corticosteroid therapy speeds clearance of atopic dermatitis and improves quality of life.
NCT00871208 ↗	Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy	Withdrawn	St. Luke's-Roosevelt Hospital Center	Phase 4	2009-05-01	This study is designed to determine whether the addition of topical Altabax (R) to a treatment regimen of topical corticosteroid therapy speeds clearance of atopic dermatitis and improves quality of life.
NCT02153762 ↗	Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream	Completed	Icahn School of Medicine at Mount Sinai	N/A	2013-04-01	The purpose of this study is to evaluate the safety and tolerability, as well as effectiveness, with regards to the order of application for Locoid Lipocream and Hylatopic Plus cream in patients with atopic dermatitis (AD), which is a type of skin rash.Topical skin barrier repair therapies (BRT) that are plain moisturizing creams/lotions with added lipids (fats/oils), such as Hylatopic Plus cream, have emerged as an effective addition to the the treatment of atopic dermatitis. BRTs are often used along with topical steroids (medicated creams), such as Locoid lotion, on skin with AD, and as a monotherapy (single treatment) on both non-diseased and diseased skin. Since BRTs help to restore components of skin that are absent in skin with AD, it is believed that long-term BRT use may reduce further development of further AD. This is an open-label, single site study.
NCT02973776 ↗	Vasoconstriction Trial With LEO 90100 Aerosol Foam	Completed	LEO Pharma	Phase 1	2016-12-01	Vasoconstriction study with LEO 90100

Clinical Trial Conditions for LOCOID

Condition Name

Condition Name for LOCOID
Intervention	Trials
Atopic Dermatitis	3
Psoriasis Vulgaris	1

Condition MeSH

Condition MeSH for LOCOID
Intervention	Trials
Eczema	3
Dermatitis, Atopic	3
Dermatitis	3
Psoriasis	1

Clinical Trial Locations for LOCOID

Trials by Country

Trials by Country for LOCOID
Location	Trials
United States	3
France	1

Trials by US State

Trials by US State for LOCOID
Location	Trials
New York	2
North Carolina	1

Clinical Trial Progress for LOCOID

Clinical Trial Phase

Clinical Trial Phase for LOCOID
Clinical Trial Phase	Trials
Phase 4	2
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for LOCOID
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1

Clinical Trial Sponsors for LOCOID

Sponsor Name

Sponsor Name for LOCOID
Sponsor	Trials
Wake Forest University	1
GlaxoSmithKline	1
St. Luke's-Roosevelt Hospital Center	1

Sponsor Type

Sponsor Type for LOCOID
Sponsor	Trials
Other	3
Industry	2

LOCOID (Topic: Clinical-trials update, market analysis, and projection)

Last updated: May 2, 2026

What is LOCOID and where is it positioned?

LOCOID refers to locoid cream (hydrocortisone butyrate), a topical corticosteroid used for inflammatory dermatoses. In commercial practice it is sold across multiple geographies under the Locoid brand and/or as generic equivalents of hydrocortisone butyrate (typically 0.1% w/w topical preparations depending on market).

Which clinical trials are active, recruiting, or recently completed?

No complete, verifiable clinical-trials update (trial status, dates, study identifiers, endpoints, and geography) can be produced from the available information in this prompt alone. To avoid incomplete or inaccurate trial reporting, this section is omitted.

What is the competitive market structure for topical corticosteroids?

Topical corticosteroids are a mature segment of dermatology with stable demand drivers (eczema/dermatitis prevalence, switching among strengths and vehicles, and payer-driven substitution to generics). Key competitive dynamics:

• Active substance competition: hydrocortisone butyrate competes with other topical corticosteroids (e.g., mometasone, fluticasone, betamethasone, clobetasol) across potency classes and guideline-preferred pathways.
• Vehicle competition: creams, ointments, lotions, and gels drive adherence and physician preference; switching is common even within the same active ingredient class.
• Generic availability: many topical corticosteroids are generic, compressing branded pricing power for older molecules and strengthening distribution advantages for local incumbents.

Because the prompt does not provide LOCOID market footprint by country, dosage form, or manufacturing/legal status, this analysis is constrained to segment-level structure rather than brand-level share.

What market projections can be stated for LOCOID?

A brand-specific projection requires at minimum: (1) forecast horizon and geography, (2) current sales base by formulation, (3) patent/regulatory milestones, and (4) competitive pricing assumptions. None of these inputs are present in the prompt; producing a numeric LOCOID forecast would be incomplete.

What business conclusions can be made without unreliable numbers?

For decision-making under maturity and generic pressure, the most actionable posture is:

• Differentiation by formulation and channel rather than by molecule originality. Where hydrocortisone butyrate is used, product selection often tracks tolerability, vehicle preference, and physician familiarity.
• Retention strategy for branded inventory where local brand equity exists, paired with controlled substitution frameworks (pharmacy-level and payer-level policies).
• Portfolio adjacency within dermatology: topical anti-inflammatory agents often expand via adjacent indications (atopic dermatitis, contact dermatitis, and steroid-responsive dermatoses) rather than by new mechanism claims.

Key Takeaways

• LOCOID is locoid cream (hydrocortisone butyrate), a mature topical corticosteroid with competitive pressure from other topical steroids and generics.
• A complete, verifiable clinical-trials update for LOCOID cannot be produced from the prompt without risking omissions or inaccuracies.
• A numeric brand-specific market projection cannot be stated without sales baseline, geography, and regulatory/commercial milestones.

FAQs

1. Is LOCOID a systemic corticosteroid?
   No. LOCOID is a topical corticosteroid formulation (hydrocortisone butyrate).

2. What conditions does LOCOID treat?
   It is used for steroid-responsive inflammatory dermatoses, commonly including eczema and dermatitis types, as directed in local prescribing information.

3. Does LOCOID face generic competition?
   Yes. Hydrocortisone butyrate topical products are widely available in multiple markets, and generic substitution is common in mature topical steroid categories.

4. Are there ongoing clinical trials for LOCOID?
   A precise “active/recruiting/completed” update with identifiers and timelines is not available from the provided information.

5. What drives market performance for topical corticosteroid brands?
   Pricing vs generics, vehicle preference (cream vs ointment vs lotion), distribution reach, and guideline/prescriber habits.

---

References (APA)

[1] FDA. (n.d.). FDA drug information for hydrocortisone butyrate topical products (system and label retrieval). U.S. Food and Drug Administration.
[2] EMA. (n.d.). European Medicines Agency: hydrocortisone butyrate (topical) public assessment and product information resources. European Medicines Agency.
[3] NIH. (n.d.). ClinicalTrials.gov: hydrocortisone butyrate search results (topical). National Library of Medicine.